Navigation Links
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform
Date:11/8/2016

HOUSTON, Nov. 8, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of Florida, Gainesville to develop a novel oncolytic virus platform.  The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers. 

A major advantage of the myxoma virus is its ability to attach to T lymphocytes and other white blood cells, which are then delivered to the patient to trigger tumor cell killing and antitumor immunity.  Myxoma virus can be armed with multiple immune stimulatory genes, a feature shared by other large DNA viruses such as herpes simplex and adenovirus.   

"The myxoma virus has unique properties for attacking cancer," said CEO Frank Tufaro, Ph.D. "We think this technology platform provides a new modality for delivery of a potent oncolytic virus to tumors by co-administering it along with T cells.  We look forward to testing this 'Trojan horse' strategy in the clinic."

"The myxoma virus is a novel oncolytic candidate that does not infect normal human cells but has a unique ability to identify the damaged signaling pathways found in the majority of human cancers; thus, resulting in productive infections in the patient's cancer cells," stated Grant McFadden, Ph.D., Professor in the Department of Molecular Genetics & Microbiology at the University of Florida, College of Medicine.

About DNAtrix
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.DNAtrix.com.

Contact 
DNAtrix
Imran Alibhai, Ph.D.
S.V.P. Business Development
ialibhai@dnatrix.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dnatrix-licenses-myxoma-virus-for-new-immunotherapy-platform-300359303.html


'/>"/>
SOURCE DNAtrix
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity
2. DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial
3. DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus
4. New Colombia Resources Sannabis Subsidiary Announces Filing for Medical Marijuana Licenses With the Ministry of Justice in order to Export Products
5. Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals to Treat Microbiome-related Inflammatory Bowel Diseases
6. Oxford BioTherapeutics Licenses Nerviano Medical Sciences Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
7. Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
8. ATCC Licenses CRISPR/Cas9 Technology from the Broad Institute
9. Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma to Enhance Anti-Infective Pipeline
10. Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research
11. ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/18/2017)... CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... 36th annual list, the most prestigious ranking of the nation's fastest-growing private companies. This ... in the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The ... “Beyond Our Imaginations: The Infinite God” is the creation of published author, Mark Lawrence, ... country. , Lawrence shares, “The problem with becoming a greater man of God is ...
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... Delaware (PRWEB) , ... August 17, 2017 , ... When ... well actually, stretcher side nurse, she took with her a dream to make nursing ... of healthcare. Specifically, ensuring communication skills were integrated into healthcare provider education. ...
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, ... for healthcare, hospitality and education, is celebrating its 30th year in business this ... begun at manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his ...
Breaking Medicine News(10 mins):